ClinicalTrials.gg
CompletedNCT03666143Updated Nov 4, 2024Results posted

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors

A Phase 1 interventional study of Sitravatinib and Tislelizumab in Advanced Solid Tumors, sponsored by BeiGene. Completed at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-04.

Sponsored by BeiGene · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
216
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This was an open-label, multicenter, non-randomized Phase 1b clinical trial for participants with histologically or cytologically confirmed locally advanced or metastatic tumors including non-squamous or squamous non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), ovarian cancer (OC), or melanoma.

Read the detailed description

All participants received sitravatinib 120 mg orally once daily in combination with tislelizumab 200 mg intravenously (IV) once every 3 weeks until occurrence of progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor. Participants were enrolled according to their tumor type and prior anti-programmed cell death protein-1 (PD-1)/PD-L1 antibody treatment into the following cohorts:

  • Cohort A: Anti-PD-1/PD-L1 antibody refractory/resistant metastatic, non-squamous NSCLC
  • Cohort B: Anti-PD-1/PD-L1 antibody naïve metastatic, non-squamous NSCLC
  • Cohort C: Anti-PD-1/PD-L1 antibody refractory/resistant metastatic or advanced RCC
  • Cohort D: Metastatic or advanced RCC without prior systemic therapy
  • Cohort E: Anti-PD-1/PD-L1 antibody naïve recurrent and platinum resistant epithelial OC
  • Cohort F: Anti-PD-1/PD-L1 antibody treated metastatic, squamous NSCLC
  • Cohort G: Anti-PD-1/PD-L1 antibody refractory/resistant unresectable or metastatic melanoma
  • Cohort H: PD-L1 positive, locally advanced or metastatic, non-squamous NSCLC without prior systemic treatment in the metastatic setting
  • Cohort I: PD-L1 positive, locally advanced or metastatic, squamous NSCLC without prior systemic treatment in the metastatic setting
02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide written and can understand and agree to comply with the requirements of the study and the Schedule of Assessments
  2. Age ≥ 18 years on the day of signing the informed consent form (or the legal age of consent in the jurisdiction in which the study is taking place)
  3. At least 1 as defined by v1.1
  4. Provide (formalin-fixed paraffin-embedded block [FFPE] with tumor tissue or unstained slides), if available.
  5. (ECOG) Performance Status ≤ 1
  6. Adequate hematologic and end-organ function
  7. Participants with inactive/asymptomatic carrier, chronic, or active virus (HBV) must have HBV deoxyribonucleic acid (DNA) \< 500 IU/mL (or 2500 copies/mL) at Screening
  8. Females of must be willing to use a highly effective method of for the duration of the study, and ≥ 120 days after the last dose of study drugs and have a negative serum pregnancy test ≤ 7 days of first dose of study drugs
  9. Non-sterile males must be willing to use a highly effective method of birth control for the duration of the study and for ≥ 120 days after the last dose of study drugs

Exclusion criteria

Exclusion Criteria:

  1. Unacceptable toxicity on prior /PD-L1 treatment
  2. Active or uncontrolled
  3. Active diseases or history of autoimmune diseases that may relapse
  4. Any active ≤ 2 years
  5. Any condition that required systemic treatment with either (> 10 mg daily of prednisone or equivalent) or other medication ≤ 14 days before first dose of study drugs
  6. History of interstitial lung disease, noninfectious pneumonitis or uncontrolled diseases, including pulmonary fibrosis, acute lung diseases, etc.
  7. Severe chronic or active infections (including tuberculosis infection, etc.) requiring systemic antibacterial, antifungal or antiviral therapy, within 14 days prior to first dose of study drugs
  8. Known history of (HIV) infection
  9. Participants with active infection
  10. Any major surgical procedure requiring general anesthesia ≤ 28 days before first dose of study drugs
  11. Prior stem cell transplantation or organ transplantation
  12. to tislelizumab or sitravatinib, to any ingredient in the formulation, or to any component of the container
  13. Bleeding or thrombotic disorders or use of anticoagulants such as warfarin or similar agents requiring therapeutic (INR) monitoring within 6 months before first dose of study drugs
  14. Concurrent participation in another therapeutic clinical trial
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
216 participants (actual)

Study arms

  • Experimental
    Sitravatinib + Tislelizumab

    Sitravatinib 120 mg was administered orally once daily in combination with tislelizumab 200 mg intravenously (IV) once every 3 weeks

    Drug: Sitravatinib · Drug: Tislelizumab

Interventions

  • Administered orally as a capsule

    Also known as: MGCD516

  • Administered intravenously

    Also known as: BGB-A317, Tevimbra

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Number of participants with treatment-emergent AEs (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs; TEAE was defined as an adverse event that had an onset date or a worsening in severity from baseline (pretreatment) on or after the first dose of study drug(s) up to 30 days following last dose of study drug(s) or initiation of a new anticancer therapy, whichever occurs first.

    Time frame: Up to approximately 4 years and 2 months

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with confirmed complete response (CR) or partial response (PR) as determined by the investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Efficacy was evaluated by cohort, as pre-specified in the statistical analysis plan.

    Time frame: Up to approximately 4 years and 2 months

  2. Duration of Response (DOR)

    DOR is defined as the time from the first determination of an objective response until the first documentation of progressive disease, whichever comes first, as assessed by the investigator using RECIST v1.1. Results are reported for cohorts with responders, defined as CR or PR. Efficacy was evaluated by cohort, as pre-specified in the statistical analysis plan.

    Time frame: Up to approximately 4 years and 2 months

  3. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants with best overall response as CR, PR, or stable disease (SD) as assessed by the investigator using RECIST v1.1. Efficacy was evaluated by cohort, as pre-specified in the statistical analysis plan.

    Time frame: Up to approximately 4 years and 2 months

  4. Progression-free Survival (PFS)

    PFS is defined as the time from the date of first dose to the date of first documentation of progressive disease or death, whichever comes first, as assessed by the investigator using RECIST v1.1. Efficacy was evaluated by cohort, as pre-specified in the statistical analysis plan.

    Time frame: Up to approximately 4 years and 2 months

  5. Maximum Plasma Concentration (Cmax) for Sitravatinib

    Time frame: Predose and up to 24 hours post dose on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 21 (C1D21); 21 days per cycle

  6. Time to Maximum Plasma Concentration (Tmax) for Sitravatinib

    Time frame: Predose and up to 24 hours post dose on C1D1 and C1D21; 21 days per cycle

  7. Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Time Point (AUC(0-t)) for Sitravatinib

    Time frame: Predose and up to 24 hours post dose on C1D1 and C1D21; 21 days per cycle

  8. Clearance After Oral Administration (CL/F) for Sitravatinib

    Time frame: Predose and up to 24 hours post dose on C1D1 and C1D21; 21 days per cycle

  9. Area Under the Plasma Concentration-time Curve During the Dosing Interval (AUC(0-tau)) for Sitravatinib

    Time frame: Predose and up to 24 hours post dose on C1D1 and C1D21; 21 days per cycle

  10. Observed Accumulation Ratio (Ro) for AUC0-tau for Sitravatinib

    Presented as geometric mean ratio and confidence interval, transformed from the difference of least square means and confidence interval of the least square differences in the logarithmic scale by exponentiation

    Time frame: Predose and up to 24 hours post dose on C1D1 and C1D21; 21 days per cycle

  11. Observed Accumulation Ratio (Ro) for Cmax for Sitravatinib

    Presented as geometric mean ratio and confidence interval, transformed from the difference of least square means and confidence interval of the least square differences in the logarithmic scale by exponentiation

    Time frame: Predose and up to 24 hours post dose on C1D1 and C1D21; 21 days per cycle

07

Results

Posted Jun 17, 2024

Participant flow

This study enrolled participants across study centers in Australia and China.

Participant flow — Overall Study
MilestoneSitravatinib + Tislelizumab
Started216
Completed0
Not completed216
Withdrew: Death158
Withdrew: Sponsor decision31
Withdrew: Withdrawal by subject11
Withdrew: Lost to follow-up5
Withdrew: Physician decision1
Withdrew: Rolled into extension study9
Withdrew: Progressive disease1

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

Number of participants with treatment-emergent AEs (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs; TEAE was defined as an adverse event that had an onset date or a worsening in severity from baseline (pretreatment) on or after the first dose of study drug(s) up to 30 days following last dose of study drug(s) or initiation of a new anticancer therapy, whichever occurs first.

Time frame:
Up to approximately 4 years and 2 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsSitravatinib + Tislelizumab
At least 1 TEAE216
At least 1 SAE120
SecondaryObjective Response Rate (ORR)

ORR is defined as the percentage of participants with confirmed complete response (CR) or partial response (PR) as determined by the investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Efficacy was evaluated by cohort, as pre-specified in the statistical analysis plan.

Time frame:
Up to approximately 4 years and 2 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsSitravatinib + Tislelizumab
Cohort A: NSCLC4.3 (0.1 to 21.9)
Cohort B: NSCLC23.8 (8.2 to 47.2)
Cohort C: RCC66.7 (9.4 to 99.2)
Cohort D: RCC0.0 (0.0 to 70.8)
Cohort E: OC28.8 (17.8 to 42.1)
Cohort F: NSCLC18.2 (5.2 to 40.3)
Cohort G: Melanoma36.0 (18.0 to 57.5)
Cohort H: NSCLC60.0 (36.1 to 80.9)
Cohort I: NSCLC30.4 (13.2 to 52.9)
SecondaryDuration of Response (DOR)

DOR is defined as the time from the first determination of an objective response until the first documentation of progressive disease, whichever comes first, as assessed by the investigator using RECIST v1.1. Results are reported for cohorts with responders, defined as CR or PR. Efficacy was evaluated by cohort, as pre-specified in the statistical analysis plan.

Time frame:
Up to approximately 4 years and 2 months
Reported as:
Median · Months
Duration of Response (DOR)
MonthsSitravatinib + Tislelizumab
Cohort A: NSCLC3.1 (NA to NA)
Cohort B: NSCLC17.9 (2.9 to NA)
Cohort C: RCC11.4 (9.7 to NA)
Cohort E: OC5.6 (2.8 to 12.5)
Cohort F: NSCLC6.9 (3.4 to NA)
Cohort G: Melanoma19.1 (2.8 to NA)
Cohort H: NSCLC9.7 (5.6 to 15.9)
Cohort I: NSCLC8.1 (5.5 to NA)
SecondaryDisease Control Rate (DCR)

DCR is defined as the percentage of participants with best overall response as CR, PR, or stable disease (SD) as assessed by the investigator using RECIST v1.1. Efficacy was evaluated by cohort, as pre-specified in the statistical analysis plan.

Time frame:
Up to approximately 4 years and 2 months
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR)
Percentage of participantsSitravatinib + Tislelizumab
Cohort A: NSCLC78.3 (56.3 to 92.5)
Cohort B: NSCLC85.7 (63.7 to 97.0)
Cohort C: RCC100.0 (29.2 to 100.0)
Cohort D: RCC100.0 (29.2 to 100.0)
Cohort E: OC79.7 (67.2 to 89.0)
Cohort F: NSCLC90.9 (70.8 to 98.9)
Cohort G: Melanoma88.0 (68.8 to 97.5)
Cohort H: NSCLC85.0 (62.1 to 96.8)
Cohort I: NSCLC78.3 (56.3 to 92.5)
SecondaryProgression-free Survival (PFS)

PFS is defined as the time from the date of first dose to the date of first documentation of progressive disease or death, whichever comes first, as assessed by the investigator using RECIST v1.1. Efficacy was evaluated by cohort, as pre-specified in the statistical analysis plan.

Time frame:
Up to approximately 4 years and 2 months
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsSitravatinib + Tislelizumab
Cohort A: NSCLC4.2 (2.7 to 5.8)
Cohort B: NSCLC7.0 (2.7 to 11.2)
Cohort C: RCC15.9 (11.1 to NA)
Cohort D: RCC2.7 (2.6 to NA)
Cohort E: OC4.1 (3.5 to 5.1)
Cohort F: NSCLC5.3 (4.1 to 8.2)
Cohort G: Melanoma6.7 (4.1 to 29.7)
Cohort H: NSCLC10.9 (5.1 to 15.3)
Cohort I: NSCLC5.4 (2.8 to 9.5)
SecondaryMaximum Plasma Concentration (Cmax) for Sitravatinib
Time frame:
Predose and up to 24 hours post dose on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 21 (C1D21); 21 days per cycle
Reported as:
Geometric mean · nanograms/milliliter (ng/mL)
Maximum Plasma Concentration (Cmax) for Sitravatinib
nanograms/milliliter (ng/mL)Sitravatinib + Tislelizumab
C1D149.49 ± 82.688
C1D2198.36 ± 68.908
SecondaryTime to Maximum Plasma Concentration (Tmax) for Sitravatinib
Time frame:
Predose and up to 24 hours post dose on C1D1 and C1D21; 21 days per cycle
Reported as:
Median · Hours (h)
Time to Maximum Plasma Concentration (Tmax) for Sitravatinib
Hours (h)Sitravatinib + Tislelizumab
C1D16.09 (2.0 to 24.8)
C1D216.08 (0.0 to 23.2)
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Time Point (AUC(0-t)) for Sitravatinib
Time frame:
Predose and up to 24 hours post dose on C1D1 and C1D21; 21 days per cycle
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Time Point (AUC(0-t)) for Sitravatinib
h*ng/mLSitravatinib + Tislelizumab
C1D1414.01 ± 115.833
C1D211539.96 ± 83.010
SecondaryClearance After Oral Administration (CL/F) for Sitravatinib
Time frame:
Predose and up to 24 hours post dose on C1D1 and C1D21; 21 days per cycle
Reported as:
Geometric mean · Liters/hour
Clearance After Oral Administration (CL/F) for Sitravatinib
Liters/hourSitravatinib + Tislelizumab
C1D172.89 ± 148.368
C1D2158.30 ± 58.470
SecondaryArea Under the Plasma Concentration-time Curve During the Dosing Interval (AUC(0-tau)) for Sitravatinib
Time frame:
Predose and up to 24 hours post dose on C1D1 and C1D21; 21 days per cycle
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve During the Dosing Interval (AUC(0-tau)) for Sitravatinib
h*ng/mLSitravatinib + Tislelizumab
C1D11050.57 ± 75.432
C1D212058.23 ± 58.470
SecondaryObserved Accumulation Ratio (Ro) for AUC0-tau for Sitravatinib

Presented as geometric mean ratio and confidence interval, transformed from the difference of least square means and confidence interval of the least square differences in the logarithmic scale by exponentiation

Time frame:
Predose and up to 24 hours post dose on C1D1 and C1D21; 21 days per cycle
Reported as:
Geometric mean · Ratio
Observed Accumulation Ratio (Ro) for AUC0-tau for Sitravatinib
RatioSitravatinib + Tislelizumab
Observed Accumulation Ratio (Ro) for AUC0-tau for Sitravatinib1.83 (1.18 to 2.82)
SecondaryObserved Accumulation Ratio (Ro) for Cmax for Sitravatinib

Presented as geometric mean ratio and confidence interval, transformed from the difference of least square means and confidence interval of the least square differences in the logarithmic scale by exponentiation

Time frame:
Predose and up to 24 hours post dose on C1D1 and C1D21; 21 days per cycle
Reported as:
Geometric mean · Ratio
Observed Accumulation Ratio (Ro) for Cmax for Sitravatinib
RatioSitravatinib + Tislelizumab
Observed Accumulation Ratio (Ro) for Cmax for Sitravatinib2.23 (1.69 to 2.95)

Adverse events

Collected over From the first dose up to 30 days after the last dose of study drug; Up to approximately 4 years and 2 months. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitravatinib + Tislelizumab158/216 (73.1%)120/216 (55.6%)213/216 (98.6%)
Most frequent serious events
Showing 10 of 124
Most frequent serious events
EventSitravatinib + Tislelizumab
DiarrhoeaGastrointestinal disorders11/216
PneumoniaInfections and infestations10/216
DeathGeneral disorders9/216
Abdominal painGastrointestinal disorders8/216
PyrexiaGeneral disorders8/216
VomitingGastrointestinal disorders7/216
Small intestinal obstructionGastrointestinal disorders6/216
DyspnoeaRespiratory, thoracic and mediastinal disorders5/216
AscitesGastrointestinal disorders4/216
Intestinal obstructionGastrointestinal disorders4/216
Most frequent other events
Showing 10 of 88
Most frequent other events
EventSitravatinib + Tislelizumab
DiarrhoeaGastrointestinal disorders114/216
Alanine aminotransferase increasedInvestigations101/216
Aspartate aminotransferase increasedInvestigations97/216
Weight decreasedInvestigations82/216
HypertensionVascular disorders81/216
HypothyroidismEndocrine disorders71/216
Decreased appetiteMetabolism and nutrition disorders71/216
NauseaGastrointestinal disorders67/216
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders63/216
VomitingGastrointestinal disorders57/216

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sitravatinib + Tislelizumab
Mean60.2 ± 11.03
Sex: Female, Male
Sex: Female, Male(Participants)Sitravatinib + Tislelizumab
Female103
Male113
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sitravatinib + Tislelizumab
Hispanic or Latino1
Not Hispanic or Latino213
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sitravatinib + Tislelizumab
American Indian or Alaska Native0
Asian143
Native Hawaiian or Other Pacific Islander2
Black or African American0
White70
More than one race0
Unknown or Not Reported1
08

Study locations

19 sites
  • Blacktown Cancer and Haematology Centre
    Blacktown, New South Wales 2148, Australia
  • Icon Cancer Foundation
    South Brisbane, Queensland 4101, Australia
  • Monash Health
    Clayton, Victoria 3168, Australia
  • Austin Health
    Heidelberg, Victoria 3084, Australia
  • Nucleus Network
    Melbourne, Victoria 3004, Australia
  • Linear Clinical Research
    Nedlands, Western Australia 6009, Australia
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • Guangdong Provincial Peoples Hospital
    Guangzhou, Guangdong 510080, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
  • Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210008, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin 300060, China
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310016, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
09

References and documents

Publications

  • Guo J, Zhou Q, Huang D, Yu X, Zhao J, Chu Q, Ma Z, Millward M, Gao B, Goh J, Markman B, Voskoboynik M, Gan H, Coward J, Chen C, Xiang X, Qui J, Xu Y, Yang L, Wu YL. A phase 1b study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients (pts) with advanced solid tumors. Chinese Society of Clinical Oncology. 2019.
  • Zhao J, Yu X, Huang D, Ma Z, Gao B, Cui J, Chu Q, Zhou Q, Sun M, Day D, Wu J, Pan H, Wang L, Voskoboynik M, Wang Z, Liu Y, Li H, Zhang J, Peng Y, Wu YL. SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer. J Immunother Cancer. 2023 Feb;11(2):e006055. doi: 10.1136/jitc-2022-006055. PubMed 36808075 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Jan 2023, 50 months.

Results were first posted in Jun 2024, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2018
First posted
Sep 11, 2018
StartActual
Nov 1, 2018
Primary completionActual
Jan 5, 2023
CompletionActual
Jan 5, 2023
Results first posted
Jun 17, 2024
Last update
Nov 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03666143
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Sep 11, 2018
Start date
Nov 1, 2018
Primary completion
Jan 5, 2023
Completion
Jan 5, 2023
Results posted
Jun 17, 2024
Last update
Nov 4, 2024

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sitravatinib · Tislelizumab

Start the discussion